249 related articles for article (PubMed ID: 22878469)
1. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
[TBL] [Abstract][Full Text] [Related]
2. Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice.
van Beuge MM; Prakash J; Lacombe M; Gosens R; Post E; Reker-Smit C; Beljaars L; Poelstra K
J Pharmacol Exp Ther; 2011 Jun; 337(3):628-35. PubMed ID: 21383021
[TBL] [Abstract][Full Text] [Related]
3. Increased contractility of hepatic stellate cells in cirrhosis is mediated by enhanced Ca2+-dependent and Ca2+-sensitization pathways.
Iizuka M; Murata T; Hori M; Ozaki H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1010-21. PubMed ID: 21393429
[TBL] [Abstract][Full Text] [Related]
4. Rho-kinase inhibitor targeting the liver prevents ischemia/reperfusion injury in the steatotic liver without major systemic adversity in rats.
Kuroda S; Tashiro H; Kimura Y; Hirata K; Tsutada M; Mikuriya Y; Kobayashi T; Amano H; Tanaka Y; Ohdan H
Liver Transpl; 2015 Jan; 21(1):123-31. PubMed ID: 25307969
[TBL] [Abstract][Full Text] [Related]
5. Amiloride reduces portal hypertension in rat liver cirrhosis.
Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
[TBL] [Abstract][Full Text] [Related]
6. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.
Klein S; Frohn F; Magdaleno F; Reker-Smit C; Schierwagen R; Schierwagen I; Uschner FE; van Dijk F; Fürst DO; Djudjaj S; Boor P; Poelstra K; Beljaars L; Trebicka J
Sci Rep; 2019 Feb; 9(1):2256. PubMed ID: 30783172
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents.
Kageyama Y; Ikeda H; Watanabe N; Nagamine M; Kusumoto Y; Yashiro M; Satoh Y; Shimosawa T; Shinozaki K; Tomiya T; Inoue Y; Nishikawa T; Ohtomo N; Tanoue Y; Yokota H; Koyama T; Ishimaru K; Okamoto Y; Takuwa Y; Koike K; Yatomi Y
Hepatology; 2012 Oct; 56(4):1427-38. PubMed ID: 22505286
[TBL] [Abstract][Full Text] [Related]
9. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
11. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
[TBL] [Abstract][Full Text] [Related]
13. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
14. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
[TBL] [Abstract][Full Text] [Related]
15. Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.
Liu J; Peng L; Yang J; Wang M; Xu S; Liu J; Han P; He J; Tian D; Zhou Q
Dig Dis Sci; 2015 Jul; 60(7):2019-29. PubMed ID: 25724163
[TBL] [Abstract][Full Text] [Related]
16. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats.
Hennenberg M; Biecker E; Trebicka J; Jochem K; Zhou Q; Schmidt M; Jakobs KH; Sauerbruch T; Heller J
Gastroenterology; 2006 Mar; 130(3):838-54. PubMed ID: 16530523
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
18. Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase.
Steib CJ; Bilzer M; Härtl JM; Beitinger F; Gülberg V; Göke B; Gerbes AL
Shock; 2010 Apr; 33(4):412-8. PubMed ID: 20118678
[TBL] [Abstract][Full Text] [Related]
19. Salvianolic acid B lowers portal pressure in cirrhotic rats and attenuates contraction of rat hepatic stellate cells by inhibiting RhoA signaling pathway.
Xu H; Zhou Y; Lu C; Ping J; Xu LM
Lab Invest; 2012 Dec; 92(12):1738-48. PubMed ID: 22986787
[TBL] [Abstract][Full Text] [Related]
20. Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632.
van Beuge MM; Prakash J; Lacombe M; Post E; Reker-Smit C; Beljaars L; Poelstra K
Pharm Res; 2011 Aug; 28(8):2045-54. PubMed ID: 21442374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
